Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ola Nilsson

Showing results (171-180 of 182) with videos related to

Pageof 19
Sort By:
Orphanet Journal of Rare Diseases|September 26, 2023
The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical dataGema Ariceta, Signe Sparre Beck-Nielsen, Annemieke M Boot, et al.
JBMR Plus|May 1, 2024
Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension periodLeanne M Ward, Wolfgang Högler, Francis H Glorieux, et al.
The Journal of Clinical Endocrinology and Metabolism|April 21, 2023
Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose LevelErik A Imel, Francis H Glorieux, Michael P Whyte, et al.
European Journal of Endocrinology|October 17, 2025
EndoCompass project: research roadmap for growth disordersEvelien F Gevers, Anita C Hokken-Koelega, Maithe Tauber, et al.
Hormone Research in Paediatrics|December 1, 2025
EndoCompass Project: Research Roadmap for Growth DisordersEvelien F Gevers, Anita C Hokken-Koelega, Maithe Tauber, et al.
Orphanet Journal of Rare Diseases|June 26, 2023
Real-world evidence in achondroplasia: considerations for a standardized data setYasemin Alanay, Klaus Mohnike, Ola Nilsson, et al.
Calcified Tissue International|January 23, 2021
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked HypophosphatemiaRaja Padidela, Michael P Whyte, Francis H Glorieux, et al.
European Journal of Endocrinology|June 23, 2026
Second interim analysis of the post-authorisation safety study (PASS) of burosumab in paediatric patients with X-linked hypophosphataemiaSigne Sparre Beck-Nielsen, Gema Ariceta, Annemieke M Boot, et al.
Lancet (London, England)|May 21, 2019
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trialErik A Imel, Francis H Glorieux, Michael P Whyte, et al.
NPJ Genomic Medicine|February 16, 2022
Expanding the mutation and phenotype spectrum of MYH3-associated skeletal disordersSen Zhao, Yuanqiang Zhang, Sigrun Hallgrimsdottir, et al.
Pageof 19

Showing results (171-180 of 182) with videos related to

Sort By:
Pageof 19
Orphanet Journal of Rare Diseases|September 26, 2023
The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical dataGema Ariceta, Signe Sparre Beck-Nielsen, Annemieke M Boot, et al.
JBMR Plus|May 1, 2024
Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension periodLeanne M Ward, Wolfgang Högler, Francis H Glorieux, et al.
The Journal of Clinical Endocrinology and Metabolism|April 21, 2023
Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose LevelErik A Imel, Francis H Glorieux, Michael P Whyte, et al.
European Journal of Endocrinology|October 17, 2025
EndoCompass project: research roadmap for growth disordersEvelien F Gevers, Anita C Hokken-Koelega, Maithe Tauber, et al.
Hormone Research in Paediatrics|December 1, 2025
EndoCompass Project: Research Roadmap for Growth DisordersEvelien F Gevers, Anita C Hokken-Koelega, Maithe Tauber, et al.
Orphanet Journal of Rare Diseases|June 26, 2023
Real-world evidence in achondroplasia: considerations for a standardized data setYasemin Alanay, Klaus Mohnike, Ola Nilsson, et al.
Calcified Tissue International|January 23, 2021
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked HypophosphatemiaRaja Padidela, Michael P Whyte, Francis H Glorieux, et al.
European Journal of Endocrinology|June 23, 2026
Second interim analysis of the post-authorisation safety study (PASS) of burosumab in paediatric patients with X-linked hypophosphataemiaSigne Sparre Beck-Nielsen, Gema Ariceta, Annemieke M Boot, et al.
Lancet (London, England)|May 21, 2019
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trialErik A Imel, Francis H Glorieux, Michael P Whyte, et al.
NPJ Genomic Medicine|February 16, 2022
Expanding the mutation and phenotype spectrum of MYH3-associated skeletal disordersSen Zhao, Yuanqiang Zhang, Sigrun Hallgrimsdottir, et al.
Pageof 19